The Landscape of EGFR Pathways and Personalized Management of Non-small-cell Lung Cancer

Liang Cheng; Shaobo Zhang; Riley Alexander; Yongxue Yao; Gregory T MacLennan; Chong-xian Pan; Jiaoti Huang; Mingsheng Wang; Rodolfo Montironi; Antonio Lopez-Beltran

Disclosures

Future Oncol. 2011;7(4):519-541. 

In This Article

Conclusion

The EGFR is an effective therapeutic target in treating NSCLC. EGFR mutations have been used as a selection criterion for EGFR TKIs and are also used as a predictive marker for responsiveness to EGFR-targeted therapy. However, evidence is beginning to demonstrate that NSCLC may be composed of multiple subsets of tumors, each with its own molecular abnormalities.

Identification of the relevant molecular subtypes of this heterogeneous disease and selecting patients for the appropriate targeting agents is critical in the personalized therapy of NSCLC. KRAS/BRAF mutations, which are mutually exclusive with EGFR mutations, are rare in NSCLC but may be important mechanisms in the etiology and prediction of resistance to EGFR TKI therapy.

In conclusion, one unifying predictive model does not apply to all tumor types, and the larger goal of discovering a predictive marker to guide patient selection for EGFR-targeted therapy remains elusive. EGFR alteration markers need to be further evaluated in combination with clinical data to provide clear rationales for future therapeutic strategies in the treatment of NSCLC.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....